CHRISTY JAGGERS: Open Payments
NPI 1295017317 · AMORY, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$676 in 35 payments from 10 companies in 2025. Trend: 2023 $960 · 2024 $622 · 2025 $676
Food & beverage: $676
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 15 | $272 |
| Calliditas Therapeutics US Inc. | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Travere Therapeutics, Inc. | 3 | $48 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $47 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| Novo Nordisk Inc | 2 | $30 |
| Amgen Inc. | 1 | $20 |
| Ardelyx, Inc. | 1 | $17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $14 |
Products named: VELPHORO, TARPEYO, JYNARQUE, Kerendia, Fabhalta, Ozempic, KRYSTEXXA, IBSRELA.
Industry payments across MS — which companies pay providers there.
